Received Jun 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 7NX57 | — |
Pediatric dose administered to an adult patient; Pediatric dose administered to an adult patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 44-year-old patient who received HBV (Engerix B pediatric) suspension for injection in pre-filled syringe (batch number 7NX57 with expiry date 12-DEC-2026) for prophylaxis. On 15-JUN-2026, the patient received Engerix B pediatric .5 ml. On 15-JUN-2026, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Pediatric dose administered to an adult patient) and underdose (Verbatim: Pediatric dose administered to an adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 15-JUN-2026 The reporter reported that a 44-year-old patient who was needing a Hepatitis B vaccine, she went to receive the adult dose of Hepatitis B, Engerix B, but instead of having the adult dose, she was administered the pediatric. The reporter mentioned that the vaccine was administered today and that the patient received only the pediatric dosage of 0.5 ml instead of the 1ml dose.